FGF23 and X-linked hypophosphatemia: However, given the likelihood of patients with FGF23 overactivity disorders, such as XLH, progressing into tertiary hyperparathyroidism on conventional therapy (DeLacey et al., 2019) it is likely that the subject would have similarly progressed into tertiary hyperparathyroidism if he remained on initial therapy.